Nasdaq · Healthcare
VERU INC. (VERU)
As-reported financials and recent SEC filings for VERU INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
—
Net income
$-22.7M
Net margin
—
Diluted EPS
—
ROE
-124.0%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | $16.9M | $16.3M | $39.4M | $61.3M |
| Gross profit | — | $5.9M | $7.6M | $30.6M | $47.9M |
| Operating income | $-24.8M | $-36.2M | $-93.8M | $-83.5M | $13.0M |
| Net income | $-22.7M | $-37.8M | $-93.2M | $-84.0M | $7.4M |
| Diluted EPS | — | — | $-6.60 | $-6.30 | $0.54 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-02
View on EDGAR →424B52026-07-02
View on EDGAR →8-K2026-06-04
View on EDGAR →S-82026-05-13
View on EDGAR →10-Q2026-05-13
View on EDGAR →8-K2026-05-13
View on EDGAR →42026-05-06
View on EDGAR →42026-05-06
View on EDGAR →Largest Healthcare peers
Go deeper on VERU
Search VERU INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.